Search clinical trials for: BI 685509

Total 1221 results

University of Chicago
CHEST Foundation

Completed

Virtual Teach-to-Goal Education vs. Brief Education for Children (V-TTG vs BI)

Asthma | Shortness of Breath | Bronchospasm

United States
Medtronic Cardiac Rhythm and Heart Failure

Completed

Application of Right Atrial Left Ventricular Fusion Pacing in Patients With CRT Indications

Heart Failure

China
Brigham and Women's Hospital
Massachusetts General Hospital

Withdrawn

Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)

Chronic Obstructive Airway Disease

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers

Healthy

Germany
Biosense Webster, Inc.

Recruiting

A Study For Treatment of Paroxysmal Atrial Fibrillation (PAF) With the OMNYPULSE Catheter and the TRUPULSE Generator (Omny-IRE)

Atrial Fibrillation

Belgium, Canada, Netherlands, Italy, Lithuania, Croatia, Germany, Czechia
Boehringer Ingelheim

Completed

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems

Hepatic Insufficiency

Germany
Boehringer Ingelheim
IQVIA global CRO

Completed

A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems

Liver Diseases | Healthy

United States
Philogen S.p.A.
Boehringer Ingelheim

Completed

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (PHIBI)

Acute Myeloid Leukemia (AML) Relapse

Germany
AbbVie
Boehringer Ingelheim

Completed

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis
Kowa Research Institute, Inc.

Completed

Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100 (OCT)

Glaucoma | Healthy | Retinal Disease

United States
Centre Hospitalier Universitaire de Nīmes
Direx Systems GmbH

Withdrawn

Low Frequency Shock Wave Therapy for Improving Post-prostatectomy Erectile Dysfunction: a Prospective Pilot Study (ProstaChoc 1)

Erectile Dysfunction

France
Guang'anmen Hospital of China Academy of Chinese...
Hubei Hospital of Traditional Chinese Medicine; Hebei Yiling Hospital; The First... and other collaborators

Unknown

The Multi-Centric Clinical Study of Chinese Medicine Intervention on Diabetes Distal Symmetric Polyneuropathy.

Type 2 Diabetes Mellitus
Boehringer Ingelheim

Completed

Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis

Liver Cirrhosis | Hepatitis C

Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

Healthy
Wang Joon Ho

Not yet recruiting

Comparison of Kinematic Movements Between ACL Deficiency With ACL Reconstruction and Healthy People

Anterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Reconstruction | Healthy People

Korea, Republic of
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
Boehringer Ingelheim
Zealand Pharma

Completed

A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

Liver Diseases | Healthy | Obesity

Germany, United States, Hungary, New Zealand, Slovakia, Poland
Oxford University Hospitals NHS Trust

Completed

Biatrial Global High-density Electroanatomical Mapping of Atrial Fibrillation (BiMap-AF)

Atrial Fibrillation

United Kingdom
University of Washington
National Cancer Institute (NCI)

Terminated

Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom Macroglobulinemia

United States
Boehringer Ingelheim

Completed

Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Recruiting

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Lung Neoplasms | Pancreatic Neoplasms | Bladder Cancer | Solid Tumors | Biliary Tract Cancer

United States, Korea, Republic of, Spain, Australia, Japan, Germany, Taiwan, Singapore, Thailand, France, Belgium, Austria, Switzerland, United Kingdom, South Africa
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy Subjects

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

Depressive Disorder, Major

United States
Boehringer Ingelheim

Completed

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Prostatic Neoplasms, Castration-Resistant

Korea, Republic of, United States, Spain, Taiwan, United Kingdom, Singapore, Hong Kong, Netherlands
Boehringer Ingelheim

Terminated

A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression

Depressive Disorder, Major

United States
Boehringer Ingelheim

Completed

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

Dermatitis, Atopic

United States, Japan, Canada
Universidade Federal do Rio Grande do Norte

Completed

Non Invasive Ventilation on Peripheral Muscle Function and Aerobic Performance (NIV)

Chronic Obstructive Pulmonary Disease

Brazil
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 456906 in Patients With Obesity

Obesity

Germany
Kyungpook National University Chilgok Hospital
Kyungpook National University Hospital

Completed

Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Stomach Neoplasms

Korea, Republic of
Boehringer Ingelheim

Completed

Olmutinib (BI 1482694) ADME Study

Healthy

Netherlands
Boehringer Ingelheim

Completed

Safety of Single Rising Doses and Relative Bioavailability of BI 691751

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses of BI 44370 BS Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Withdrawn

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667

Healthy
Boehringer Ingelheim

Completed

Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

Solid Tumors

Spain, Canada, United States, Sweden
Boehringer Ingelheim

Terminated

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Purpura, Thrombocytopenic, Idiopathic

United States
Boehringer Ingelheim

Terminated

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)

Neoplasms

United States, Spain, Japan, Netherlands
AbbVie

Completed

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
University of Chicago

Completed

Teaching Use of Respiratory Inhalers (TURI) (TURI)

Asthma | COPD

United States
Albert Einstein College of Medicine

Terminated

Bi-Level Positive Airway Ventilation for Acute Chest Syndrome

Sickle Cell Anemia | Acute Chest Syndrome

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

Hemorrhage

Belgium
Queen's University
Canadian Institutes of Health Research (CIHR)

Completed

Prevention and Reduction of Obesity Through Active Living (PROACTIVE)

Obesity

Canada
Daping Hospital and the Research Institute of Surgery...

Unknown

A Study of Bi-Level Positive Airway Pressure (BIPAP) Versus Non Invasive Positive Pressure Ventilation (NIPPV) for Neonatal Respiratory Failure (BIPAP)

Neonatal Respiratory Failure

China
National Cancer Institute (NCI)

Completed

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
Biosense Webster, Inc.

Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF (SMARTPULSE PAF)

Drug Refractory Paroxysmal Atrial Fibrillation

United States
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Wet Macular Degeneration

United Kingdom, United States, Germany
AbbVie

Completed

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (IMMPRESS)

Psoriasis

Russian Federation
University of Pittsburgh
Merck Sharp & Dohme LLC; RTI International; Rite Aid Corp.; Pharmacy Quality Alliance

Completed

Effect of Community Pharmacist Intervention on Adherence to Long-Term Medications (ECO-PHIL)

Medication Adherence

United States

3

Subscribe